Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

× No keyword cloud information.

45 in total

1. Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study.

Authors: Olivier Mir; Jean-Philippe Durand; Pascaline Boudou-Rouquette; Julie Giroux; Romain Coriat; Anatole Cessot; Stanislas Ropert; François Goldwasser; Raphaël Gaillard
Journal: Support Care Cancer Date: 2012-05-30 Impact factor: 3.603

2. The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.

Authors: Meredith Cummins; Nick Pavlakis
Journal: Ther Adv Med Oncol Date: 2013-09 Impact factor: 8.168

3. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.

Authors: A Bianchi; L De Marinis; A Fusco; F Lugli; L Tartaglione; D Milardi; M Mormando; A P Lassandro; R Paragliola; C A Rota; S Della Casa; S M Corsello; M G Brizi; A Pontecorvi
Journal: J Endocrinol Invest Date: 2011-11-07 Impact factor: 4.256

4. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.

Authors: Núria Buil-Bruna; Marion Dehez; Amandine Manon; Thi Xuan Quyen Nguyen; Iñaki F Trocóniz
Journal: AAPS J Date: 2016-02-23 Impact factor: 4.009

Review 5. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.

Authors: Javier Molina-Cerrillo; Teresa Alonso-Gordoa; Olga Martínez-Sáez; Enrique Grande
Journal: Oncologist Date: 2016-04-22

6. Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma.

Authors: Kazuhiko Kasuya; Yuichi Nagakawa; Minako Suzuki; Yoshiaki Suzuki; Bunso Kyo; Satoru Suzuki; Takaaki Matsudo; Takao Itoi; Akihiko Tsuchida; Tatsuya Aoki
Journal: Exp Ther Med Date: 2012-01-18 Impact factor: 2.447

Review 10. Pancreatic neuroendocrine tumors.

Authors: Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal: Indian J Gastroenterol Date: 2012-10-03

Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.